Abstract: The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.

Abstract: The present invention provides peptides and supported peptides that bind to FGF-5.

Abstract: The present invention relates to a method for liquefying starch comprising contacting a slurry of a starch substrate with an enzyme composition comprising a phytase and an alpha amylase. The invention also relates to an enzyme mixture comprising a phytase derived from Buttiauxella sp. and variants thereof and an alpha amylase.

Abstract: DNA is provided which encodes an enzyme having phytase activity isolated from Penicillium, Fusarium, Humicola and Emericella. Also provided for is a method of isolating DNA encoding an enzyme having phytase activity from organisms which possess such DNA, transformation of the DNA into a suitable host organism, expression of the transformed DNA and the use of the expressed phytase protein in feed as a supplement.

Abstract: The present invention provides peptides and supported peptides that bind to FGF-5.

Abstract: DNA is provided which encodes an enzyme having phytase activity isolated from Penicillium, Fusarium, Humicola and Emericella. Also provided for is a method of isolating DNA encoding an enzyme having phytase activity from organisms which possess such DNA, transformation of the DNA into a suitable host organism, expression of the transformed DNA and the use of the expressed phytase protein in feed as a supplement.

Abstract: Described herein are protease inhibitors, variants thereof and methods for their production.

Abstract: The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.

Abstract: The present invention provides compositions and methods related to the expression of Bowman-Birk protease inhibitors and variants thereof in bacterial species. The present invention further provides fusion nucleic acids, vectors, fusion polypeptides, and processes for obtaining the Bowman-Birk protease inhibitors.

Abstract: Described herein are protease inhibitors, variants thereof and methods for their production.

Abstract: The present invention provides peptides and supported peptides that bind TGF? (molecules. In some particularly preferred embodiments, the TGF? binding molecules bind TGF?-1, while in other embodiments, the TGF? binding molecules bind TGF?-2.

Abstract: Described herein are protease inhibitors, variants thereof and methods for their production.

Abstract: DNA is provided which encodes an enzyme having phytase activity isolated from Penicillium, Fusarium, Humicola and Emericella. Also provided for is a method of isolating DNA encoding an enzyme having phytase activity from organisms which possess such DNA, transformation of the DNA into a suitable host organism, expression of the transformed DNA and the use of the expressed phytase protein in feed as a supplement.

Abstract: The present invention provides methods and composition suitable for the identification and modification of allergenic proteins. More particularly, the present invention provides methods and compositions for the identification and modification of epitopes of allergenic food proteins, as well as epitopes of potentially allergenic food proteins.

Abstract: A method is provided for bleaching a non-cotton cellulosic fiber, yarn or fabric by contacting said fiber, yarn or fabric with a hemicellulase enzyme for a time and under conditions suitable to produce a whitening of said fiber, yarn or fabric.

Abstract: Described herein are methods for the production of monoclonal antibodies in filamentous fungi host cells. The monoclonal antibodies are expressed as full-length fusion proteins that retain functional antigen binding and antibody-dependent cellular cytotoxicity capabilities. Improvements in the cleavage of the glucoamylase-light chain fusion protein to yield a mature antibody are also provided. The antibodies produced in filamentous fungi show equivalent pharmacokinetic disposition to antibodies produced in mammalian cells.

Abstract: The invention includes novel fusion nucleic acids encoding fusion polypeptides which when expressed in a filamentous fungus result in the expression of fusion polypeptides. The fusion nucleic acids comprise four nucleic acids which encode a fusion polypeptide comprising first, second, third and fourth amino acid sequences. The first nucleic acid encodes a signal polypeptide functional as a secretory sequence in a first filamentous fungus. The second nucleic acid encodes a secreted polypeptide or functional portion thereof which is normally secreted from the same filamentous fungus or a second filamentous fungus. The third nucleic acid encodes a cleavable linker while the fourth nucleic acid comprises at least two nucleic acids encoding desired polypeptides.

Abstract: The invention includes novel fusion nucleic acids encoding fusion polypeptides which when expressed in a filamentous fungus result in the expression of fusion polypeptides. The fusion nucleic acids comprise four nucleic acids which encode a fusion polypeptide comprising first, second, third and fourth amino acid sequences. The first nucleic acid encodes a signal polypeptide functional as a secretory sequence in a first filamentous fungus. The second nucleic acid encodes a secreted polypeptide or functional portion thereof which is normally secreted from the same filamentous fungus or a second filamentous fungus. The third nucleic acid encodes a cleavable linker while the fourth nucleic acid comprises at least two nucleic acids encoding desired polypeptides.

Abstract: The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.

Abstract: Novel alpha-amylase mutants derived from the DNA sequences of naturally occurring or recombinant alpha-amylases are disclosed. The mutant alpha-amylases, in general, are obtained by in vitro modifications of a precursor DNA sequence encoding the naturally occurring or recombinant alpha-amylase to generate the substitution (replacement) or deletion of one or more oxidizable amino acid residues in the amino acid sequence of a precursor alpha-amylase. Such mutant alpha-amylases have altered oxidative stability and/or altered pH performance profiles and/or altered thermal stability as compared to the precursor. Also disclosed are detergent and starch liquefaction compositions comprising the mutant amylases, as well as methods of using the mutant amylases.